Antitumor Activity of HKI-272, an Orally Active, Irreversible Inhibitor of the HER-2 Tyrosine Kinase

By S. Rabindran, C. Discafani, E. Rosfjord, M. Baxter, M. Floyd, J. Golas, W. Hallett, Bernard D. Johnson, R. Nilakantan, E. Overbeek and 6 more. Cancer Research, 2004

625 citations recorded by the source corpus.

Subfields: Oncology, Radiology, Nuclear Medicine and Imaging

View Paper: https://www.semanticscholar.org/paper/abf1a9d54a2c3abc10214bebcd85182b601f9be3

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Oncology

1. Lewis C. Cantley
2. G. Shapiro
3. Nathanael S. Gray
4. J. Settleman
5. C. Sawyers
6. R. Weinberg

In Radiology, Nuclear Medicine and Imaging

1. Lewis C. Cantley

Citations in the corpus

• Kinase-targeted cancer therapies: progress, challenges and future directions (2018, background): “The covalent kinase inhibitors bind to a cysteine residue in or around the active site, thus preventing the binding of ATP to the protein kinase [117, 127].”
• BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models (2008, background): “ATP-binding site of the kinase domains of EGFR (Cys 773) and HER2 (Cys 805) (Rabindran et al., 2004; Eskens et al., 2008).”
• Targeting the PI5P4K lipid kinase family in cancer using covalent inhibitors (2020, background): “, 2007), EGFR inhibitors neratinib (Rabindran et al., 2004), afatinib (Li et al.”
• Epidermal growth factor receptor mutations in lung cancer (2007, background): “Previous studies from our laboratory have shown that the irreversible dual EGFR and ERBB2 inhibitors, HKI-272 (Ref”